↓ Skip to main content

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial

Overview of attention for article published in Lancet Oncology, December 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter
44 X users
facebook
2 Facebook pages

Citations

dimensions_citation
102 Dimensions

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
Published in
Lancet Oncology, December 2018
DOI 10.1016/s1470-2045(18)30676-4
Pubmed ID
Authors

Javier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, Andres Redondo, Daniel Bernabeu, Enrique de Alava, Paolo G Casali, Antoine Italiano, Antonio Gutierrez, David S Moura, Maria Peña-Chilet, Juan Diaz-Martin, Michele Biscuola, Miguel Taron, Paola Collini, Dominique Ranchere-Vince, Xavier Garcia Del Muro, Giovanni Grignani, Sarah Dumont, Javier Martinez-Trufero, Emanuela Palmerini, Nadia Hindi, Ana Sebio, Joaquin Dopazo, Angelo Paolo Dei Tos, Axel LeCesne, Jean-Yves Blay, Josefina Cruz

X Demographics

X Demographics

The data shown below were collected from the profiles of 44 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 94 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 13%
Student > Ph. D. Student 11 12%
Student > Postgraduate 8 9%
Student > Bachelor 6 6%
Student > Master 5 5%
Other 19 20%
Unknown 33 35%
Readers by discipline Count As %
Medicine and Dentistry 32 34%
Biochemistry, Genetics and Molecular Biology 5 5%
Nursing and Health Professions 5 5%
Agricultural and Biological Sciences 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 10 11%
Unknown 36 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2020.
All research outputs
#1,343,504
of 25,385,509 outputs
Outputs from Lancet Oncology
#1,533
of 6,885 outputs
Outputs of similar age
#30,322
of 443,612 outputs
Outputs of similar age from Lancet Oncology
#42
of 131 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,885 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,612 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.